|
Delayed
Nasdaq
04:00:00 15/08/2025 HKT
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.84B 2.66B 2.44B 4.57B 318B 4.63B 31.45B 12.26B 160B 12.47B 12.2B 528B | P/E 2023 |
-317x | P/E 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 2.98B 2.79B 2.55B 4.79B 333B 4.85B 32.93B 12.84B 167B 13.06B 12.77B 553B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 30/09/25 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 30/07/25 | Amedisys: Q2 Earnings Snapshot | AQ |
| 30/07/25 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 30/07/25 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 24/04/25 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 3 years | 82.15 |  | 101.02 |
| 5 years | 69.36 | | 188.88 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 06/10/2017 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 01/01/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/8/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/8/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/8/25 | Issuer sale | Chief Executive Officer | 520,347 | 1.5886% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 1.92B 1.79B 1.64B 3.08B 214B 3.12B 21.18B 8.26B 107B 8.4B 8.21B 356B | 2.35B 2.01B 1.88B 1.72B 3.23B 225B 3.28B 22.24B 8.67B 113B 8.82B 8.63B 373B |
| Net income | -9.75M -8.35M -7.81M -7.15M -13.42M -933M -13.6M -92.3M -35.99M -468M -36.6M -35.8M -1.55B | 43.23M 37.03M 34.65M 31.72M 59.53M 4.14B 60.31M 409M 160M 2.08B 162M 159M 6.87B |
| Net Debt | 361M 309M 289M 265M 497M 34.52B 503M 3.42B 1.33B 17.34B 1.35B 1.33B 57.35B | 156M 134M 125M 114M 215M 14.93B 218M 1.48B 576M 7.5B 586M 573M 24.81B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
